Eric Benevich - 09 Sep 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: NBIX
Reported as of: 09 Sep 2026
Net transaction value: -$333,030
SEC form: 4
Accepted by SEC: 10 Sep 2026, 20:29:07 UTC
Prior SEC filing: 13 May 2026
Next SEC filing: 15 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eric Benevich filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 10 Sep 2026.

Key facts

This page summarizes Eric Benevich's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 20:29.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: -$333,030.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643653 Primary reporting owner

BENEVICH ERIC

Relationship: Chief Commercial Officer
Address: 6027 EDGEWOOD BEND CT., SAN DIEGO
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,194
Change %: +5%
Price: $43.24^*
Shares after: 66,562
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1

NBIX transaction

Common Stock

Sale

Transaction value: $333,030
Shares: -2,154
Change %: -3.2%
Price: $154.61
Shares after: 64,408
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value
Shares: -3,194
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,194
Exercise price: $43.24
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Footnote F2

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F3

The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.